Title of article
Acute Immune-Mediated Thrombocytopenia due to Oxaliplatinand Irinotecan Therapy
Author/Authors
Sidhu, Gurinder S. Department of Medicine - Division of Hematology and Oncology - State University of New York Downstate Medical Center - Brooklyn, USA , Tam, Eric L. Department of Medicine - Division of Hematology and Oncology - State University of New York Downstate Medical Center - Brooklyn, USA , Draksharam, Padma L. Department of Medicine - Division of Hematology and Oncology - State University of New York Downstate Medical Center - Brooklyn, USA , Park, Jennifer A. Department of Medicine - Division of Hematology and Oncology - State University of New York Downstate Medical Center - Brooklyn, USA
Pages
6
From page
1
To page
6
Abstract
We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated withfluorouracil,leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without anysignificant hematological side effects, but after the 14th cycle, she developed melena and was admitted for severethrombocytopenia. After supportive care, the platelet counts rapidly improved to 76,000/μL. Upon initiation of FOLFIRI andcetuximab chemotherapy, she again developed rectal bleeding and severe thrombocytopenia with a platelet count of 6000/μL.Lab testing was positive for oxaliplatin and irinotecan drug-dependent platelet antibodies onflow cytometry assay. Drug-induced thrombocytopenia (DITP) is associated with several classes of drugs with several proposed underlying mechanisms.Prospective studies are needed to further address different mechanisms of drug-induced thrombocytopenia
Keywords
Acute Immune-Mediated Thrombocytopenia due , Oxaliplatinand Irinotecan Therapy , FOLFOX , DITP
Journal title
Case Reports in Oncological Medicine
Serial Year
2019
Record number
2610282
Link To Document